ArticleScientific reports2026
Analysis of the mechanism and prognostic value of PRKCQ-AS1 in inhibiting the progression of lung adenocarcinoma via regulating the PD-1/PD-L1 pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To investigate the expression profile and biological functions of long non-coding RNA PRKCQ-AS1 in lung adenocarcinoma (LUAD) and to elucidate the underlying mechanism by which PRKCQ-AS1 modulates tumor immune escape through regulation of the PD-1/PD-L1 signaling pathway. The expression levels and clinical significance of PRKCQ-AS1 in LUAD were analyzed using data from The Cancer Genome Atlas (TCGA) database and validated with clinical specimens. A competitive endogenous RNA (ceRNA) regulatory network mediated by PRKCQ-AS1 was constructed, followed by functional enrichment analysis. PRKCQ-AS1 expression was modulated in NCI-H1395 cells via transfection. Cellular malignant phenotypes were assessed using CCK-8, Transwell, and flow cytometry assays. The regulatory effects on PD-1 and PD-L1 expression were confirmed by RT-qPCR and Western blotting. PRKCQ-AS1 was significantly downregulated in LUAD tissues and negatively correlated with advanced TNM stage and poor prognosis. Mechanistic analyses indicated that the ceRNA network involving PRKCQ-AS1 was strongly associated with immune-related pathways. Silencing of PRKCQ-AS1 markedly enhanced proliferation, migration, and invasion of LUAD cells while suppressing apoptosis in vitro. Notably, knockdown of PRKCQ-AS1 led to a significant upregulation of PD-1 and PD-L1 expression, suggesting that PRKCQ-AS1 inhibits immune escape by suppressing the PD-1/PD-L1 signaling axis. PRKCQ-AS1 acts as a potential tumor suppressor in LUAD. Its downregulation not only promotes tumor progression but also facilitates immune escape through dysregulation of the PD-1/PD-L1 pathway. Therefore, PRKCQ-AS1 may serve as a promising biomarker for prognostic evaluation and a potential therapeutic target for immunotherapy in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.